{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:07:14Z","timestamp":1740128834843,"version":"3.37.3"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,12,20]],"date-time":"2020-12-20T00:00:00Z","timestamp":1608422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,15]]},"DOI":"10.1093\/cid\/ciaa1874","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T04:17:03Z","timestamp":1608092223000},"page":"e1167-e1168","source":"Crossref","is-referenced-by-count":3,"title":["How Second-Line Injectable Drugs Work"],"prefix":"10.1093","volume":"72","author":[{"given":"Armand","family":"Van Deun","sequence":"first","affiliation":[{"name":"Independent Consultant, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1205-1484","authenticated-orcid":false,"given":"Tom","family":"Decroo","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine, Unit of HIV and TB, Department of Clinical Sciences, Antwerp, Belgium"},{"name":"Research Foundation Flanders, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,12,20]]},"reference":[{"key":"2021061514014734600_CIT0001","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa621","article-title":"Aminoglycosides and capreomycin in the treatment of multidrug-resistant tuberculosis: individual patient data meta-analysis of 12 030 patients from 25 countries, 2009\u20132016","author":"Cegielski","year":"2020;","journal-title":"Clin Infect Dis"},{"key":"2021061514014734600_CIT0002","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"key":"2021061514014734600_CIT0003","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5588\/ijtld.17.0660","article-title":"Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs","volume":"22","author":"Van Deun","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021061514014734600_CIT0004","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0140-6736(13)62675-6","article-title":"Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study","volume":"383","author":"Pietersen","year":"2014","journal-title":"Lancet"},{"key":"2021061514014734600_CIT0005","doi-asserted-by":"crossref","first-page":"e0238016","DOI":"10.1371\/journal.pone.0238016","article-title":"Injectables\u2019 key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes","volume":"15","author":"Decroo","year":"2020","journal-title":"PLoS One"},{"key":"2021061514014734600_CIT0006","first-page":"91","article-title":"Treatment of tuberculosis. The Mitchell Lecture 1979","volume":"14","author":"Mitchison","year":"1980","journal-title":"J Roy Coll Phys London"},{"key":"2021061514014734600_CIT0007","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1086\/424849","article-title":"Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling","volume":"190","author":"Gumbo","year":"2004","journal-title":"J Infect Dis"},{"key":"2021061514014734600_CIT0008","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1128\/AAC.49.8.3178-3181.2005","article-title":"Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance","volume":"49","author":"Gumbo","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2021061514014734600_CIT0009","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/cid\/ciy618","article-title":"Gatifloxacin pharmacokinetics\/pharmacodynamics-based optimal dosing for pulmonary and meningeal multidrug-resistant tuberculosis","volume":"67","author":"Deshpande","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021061514014734600_CIT0010","doi-asserted-by":"crossref","first-page":"965","DOI":"10.5588\/ijtld.19.0053","article-title":"Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB","volume":"23","author":"Van Deun","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021061514014734600_CIT0011","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/cid\/ciu572","article-title":"Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis","volume":"59","author":"Cegielski","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2021061514014734600_CIT0012","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1128\/JCM.00240-10","article-title":"Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections","volume":"48","author":"Jur\u00e9en","year":"2010","journal-title":"J Clin Microbiol"},{"key":"2021061514014734600_CIT0013","doi-asserted-by":"crossref","first-page":"e33275","DOI":"10.1371\/journal.pone.0033275","article-title":"Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review","volume":"7","author":"Georghiou","year":"2012","journal-title":"PLoS One"},{"key":"2021061514014734600_CIT0014","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1128\/AAC.04438-14","article-title":"Disparities in capreomycin resistance levels associated with the rrs A1401G mutation in clinical isolates of Mycobacterium tuberculosis","volume":"59","author":"Reeves","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1874\/36246105\/ciaa1874.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/12\/e1167\/38651708\/ciaa1874.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/12\/e1167\/38651708\/ciaa1874.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T14:03:08Z","timestamp":1623765788000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/72\/12\/e1167\/6042343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,20]]},"references-count":14,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,20]]},"published-print":{"date-parts":[[2021,6,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1874","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"type":"print","value":"1058-4838"},{"type":"electronic","value":"1537-6591"}],"subject":[],"published-other":{"date-parts":[[2021,6,15]]},"published":{"date-parts":[[2020,12,20]]}}}